Hanmi Pharmaceutical Co., Ltd. (KRX: 002390) is a major South Korean pharmaceutical company headquartered in Seoul, South Korea. Founded in 1973, Hanmi has established itself as one of Korea's leading innovative drug developers, with a pipeline spanning CNS disorders, oncology, metabolic diseases, and rare conditions.
Hanmi represents one of the most advanced Korean pharmaceutical companies in terms of global drug development, with multiple compounds in international clinical trials and partnerships with major pharmaceutical companies. The company's focus on neurodegenerative diseases includes innovative programs targeting Parkinson's disease and Alzheimer's disease through multiple mechanisms.
| Attribute |
Details |
| Founded |
1973 |
| Headquarters |
Seoul, South Korea |
| Stock Exchange |
Korea Exchange (KRX) |
| Ticker |
002390 |
| CEO |
Kwon Seong-joon |
| Website |
hanmi.co.kr |
| Focus |
Innovative drug development |
Hanmi Pharmaceutical was founded in 1973, initially focusing on generic pharmaceutical production. Over its first two decades, Hanmi built manufacturing capabilities and established a domestic market presence.
The company transformed into an innovation-driven pharmaceutical company:
- Established dedicated R&D facilities
- Developed proprietary technology platforms
- Initiated first innovative drug programs
- Began international partnership development
Hanmi has expanded its global presence:
- Multiple compounds in global clinical trials
- Strategic partnerships with major pharma companies
- Expansion of manufacturing capabilities
- Development of advanced technology platforms
Hanmi's proprietary Lunos™ technology enables long-acting formulations for CNS drugs:
- Extended half-life: Reduced dosing frequency
- Improved patient compliance: Less frequent administration
- Sustained drug delivery: Consistent therapeutic exposure
- Multiple formulations: Injection, oral, and other delivery forms
The platform is particularly relevant for CNS disorders where patient compliance is challenging:
- Parkinson's disease (dopaminergic agents)
- Alzheimer's disease (chronic symptomatic treatments)
- Psychiatric disorders
Hanmi has developed mRNA-based therapeutics:
- mRNA-based protein replacement therapy
- Targeting GBA deficiency
- Applications in Parkinson's disease with GBA mutations
- mRNA delivery optimization
- Protein expression optimization
- Manufacturing process development
- Novel formulation technologies: Enhanced drug delivery
- Biologics development: Antibody and protein therapeutics
- Combination therapy: Multi-mechanism approaches
| Attribute |
Details |
| Mechanism |
LRRK2 kinase inhibition |
| Target |
LRRK2 mutations in PD |
| Stage |
Phase 2 |
| Status |
Active |
Scientific Rationale: LRRK2 (Leucine-rich repeat kinase 2) mutations are among the most common genetic causes of Parkinson's disease. LRRK2 inhibitors represent a disease-modifying approach:
- Targeting the kinase activity of mutant LRRK2
- Potential to slow disease progression
- Relevant for patients with LRRK2 mutations (5-10% of PD)
- May benefit sporadic PD as well
| Attribute |
Details |
| Mechanism |
GBA gene delivery |
| Target |
GBA mutations in PD |
| Stage |
Preclinical |
| Status |
Research |
Scientific Rationale: GBA (glucocerebrosidase) mutations are significant risk factors for Parkinson's disease:
- GBA mutations increase PD risk 5-10x
- Associated with earlier onset and cognitive decline
- Gene therapy could restore enzyme function
- May benefit both GBA-associated and sporadic PD
| Attribute |
Details |
| Mechanism |
RNA interference targeting alpha-synuclein |
| Target |
Alpha-synuclein expression |
| Stage |
Discovery |
| Status |
Early research |
Scientific Rationale: Alpha-synuclein aggregation is central to PD pathogenesis:
- Reducing alpha-synuclein production may slow progression
- RNAi approach provides sequence-specific knock-down
- Potential for disease modification
¶ HM-40001: Anti-Amyloid Antibody
| Attribute |
Details |
| Mechanism |
Monoclonal antibody against Aβ |
| Target |
Amyloid-beta plaques |
| Stage |
Phase 1 |
| Status |
Recruiting |
Scientific Rationale: Amyloid hypothesis remains central to AD therapeutic development:
- Amyloid-beta accumulation is an early trigger
- Antibody-mediated clearance has shown biomarker effects
- Earlier intervention may provide greater benefit
| Attribute |
Details |
| Mechanism |
BACE1 (Beta-secretase) inhibition |
| Target |
Amyloid-beta production |
| Stage |
Phase 2 |
| Status |
Active |
Scientific Rationale: BACE1 is the enzyme that initiates amyloid-beta production:
- Inhibiting BACE1 reduces Aβ generation
- Multiple BACE1 inhibitors have been in development
- Challenges include safety and efficacy balance
Hanmi maintains a broad research focus:
- Parkinson's disease: LRRK2, GBA, alpha-synuclein approaches
- Alzheimer's disease: Amyloid, BACE, tau approaches
- Huntington's disease: Emerging programs
- Kinase inhibitors: Multiple targets across cancer types
- Immuno-oncology: Checkpoint modulation and CAR-T approaches
- GLP-1 analogs: Diabetes and obesity treatments
- Novel antidiabetics: Beyond incretin-based approaches
- Orphan drug development: Unmet medical needs
- Pediatric conditions: Specialized programs
Hanmi has established strategic partnerships with major pharmaceutical companies:
- Strategic partnership for metabolic diseases
- Co-development of certain therapeutic programs
- Commercialization collaboration
- Licensing agreement for oncology pipeline
- International development support
- Commercialization partnerships
- Distribution partnership
- Market access collaboration
- Regional commercial operations
¶ Competitive Landscape
Hanmi competes in the global pharmaceutical market:
- Daewoong Pharmaceutical: Korean peer with CNS focus
- JW Pharmaceutical: Korean innovative drug developer
- Samsung BioLogics: Korean biologics manufacturer
- Pfizer: Global CNS programs
- Roche: Alzheimer's and Parkinson's pipelines
- Biogen: CNS-focused biotech
Hanmi differentiates through:
- Multiple innovative mechanisms in neurodegeneration
- Proprietary technology platforms
- Strong Korean market position
- International partnership network
As a KRX-listed company, Hanmi maintains:
- Regular financial disclosures
- R&D investment focus
- Growing international revenue
Hanmi's future development includes:
- Continued Phase 2 trials for LRRK2 inhibitor
- BACE1 inhibitor development
- GBA gene therapy advancement
- mRNA platform expansion
- Additional novel modalities
- Formulation technology improvements
- US and EU clinical development
- Global partnership expansion
- Market access development